Evidence map›Paper›PMID 39802393›Full record

ArticleBiochemistry and biophysics reports2025

Assessing the prevalence of neutralizing antibodies (NAbs) to SARS-CoV-2 during three years of the COVID-19 pandemic.

Marina Dos Santos Barreto, Ronaldy Santana Santos, Eloia Emanuelly Dias Silva, Deise Maria Rego Rodrigues Silva, Pedro Henrique Macedo Moura, Pamela Chaves de Jesus, Jessiane Bispo de Souza, Lucas Alves da Mota Santana, Adriana Gibara Guimarães, Lysandro Pinto Borges

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marina Dos Santos BarretoDepartment of Pharmacy, Federal University of Sergipe, São Cristóvão, 49100-000, SE, Brazil.
Ronaldy Santana SantosDepartment of Pharmacy, Federal University of Sergipe, São Cristóvão, 49100-000, SE, Brazil.
Eloia Emanuelly Dias SilvaDepartment of Biology, Federal University of Sergipe, São Cristóvão, 49100-000, SE, Brazil.
Deise Maria Rego Rodrigues SilvaDepartment of Pharmacy, Federal University of Sergipe, São Cristóvão, 49100-000, SE, Brazil.
Pedro Henrique Macedo MouraDepartment of Pharmacy, Federal University of Sergipe, São Cristóvão, 49100-000, SE, Brazil.
Pamela Chaves de JesusDepartment of Pharmacy, Federal University of Sergipe, São Cristóvão, 49100-000, SE, Brazil.
Jessiane Bispo de SouzaDepartment of Pharmacy, Federal University of Sergipe, São Cristóvão, 49100-000, SE, Brazil.
Lucas Alves da Mota SantanaGraduate Program in Dentistry, Federal University of Sergipe, São Cristóvão, 49100-000, SE, Brazil.
Adriana Gibara GuimarãesDepartment of Pharmacy, Federal University of Sergipe, São Cristóvão, 49100-000, SE, Brazil.
Lysandro Pinto BorgesDepartment of Pharmacy, Federal University of Sergipe, São Cristóvão, 49100-000, SE, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of COVID-19 vaccines has been an important step in the fight against the pandemic. However, it is still necessary to understand the influence of factors that can alter the immune response. In general, doses need to be updated frequently, and care must be taken to control the virus that is still circulating worldwide. In this study, we evaluated the neutralizing antibodies (NAbs) against SARS-CoV-2 in northeast Brazil. The study was divided into three phases (T1, T2, and T3) and included 297 participants. The three phases occurred in three different years of the pandemic (2021, 2022 and 2023). We obtained higher mean NAbs in T2 and T3 when most of the participants had already completed their vaccination program. No significant difference in the distribution of NAbs and sex was observed (p > 0.05). It was shown that there is a difference in the expression of NAbs in the different amounts of doses, with individuals with no dose obtaining a significantly lower average than those who took the vaccine. Regarding age, the average NAbs were higher with increasing age. In this study, we assess the prevalence of NAbs in three pandemic phases, making it possible to understand the importance of vaccine updating in maintaining immunity.

Indexed as

BrazilCOVID-19Neutralizing antibodiesPandemicVaccine

Identifiers

PMID39802393
PMCPMC11721800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.